Menu
← Oncology Approval Tracker
FDA DECISION ·
Ermeza oral solution
levothyroxine sodium · Mylan Pharmaceuticals / Viatris
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
An oral levothyroxine solution for thyrotropin suppression as an adjunct to surgery and radioiodine in patients with thyrotropin-dependent well-differentiated thyroid cancer, including pediatric patients.
LAMPGEN ANALYSIS
Why it matters
The formulation supplies an additional way to deliver thyroid-hormone suppression after definitive treatment.
What research teams should watch
Record the formulation, target TSH and thyroid-function follow-up schedule when reconciling cancer-related use.
PRIMARY RECORDS